Jobs / United States / Novartis Pharmaceuticals Corporation
Therapeutic Area Biomarker Director – Cardiovascular and Metabolism
Novartis Pharmaceuticals Corporation · 🇺🇸 Cambridge (USA)
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Novartis Pharmaceuticals Corporation paid sponsored hires in similar roles23 certified filings for “Director, Forecasting-CV” (Data Scientists) in NJ: $170k–$170k, median $170k. Most were filed at wage level IV (83%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Last confirmed live 1 day agoWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Novartis Pharmaceuticals Corporation
The US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Novartis Pharmaceuticals Corporation →
About the role
Job Description Summary As a Cardiovascular and Metabolism (CVM) Therapeutic Area Biomarker Lead (TABL) (Director) you will lead the CVM disease area biomarker matrix team and be responsible for the development and implementation of “fit for purpose” biomarker strategies and providing an effective interface for transitioning projects from early to later stage clinical development. You will be a core member of CVM clinical project teams, engaged in Translational Data Science teams, and provide therapeutic area line function review for clinical protocols. As a TABL you will lead efforts to identify, develop, and drive disease, mechanistic and compound biology that serves the clinical and precision medicine approaches for the multi-indication CVM portfolio that focuses on heart failure, atherosclerosis, obesity and atrial fibrillation indications. Job Description #LI-Hybrid This hybrid role can be based in Cambridge US, or Basel, Switzerland. For Switzerland posting please refer to REQ-10086998 Therapeutic Area Biomarker Director – Cardiovascular and Metabolism Key Responsibilities: • Delivering clinical project and disease biomarker strategies and plans across the early through late phase within the Cardiovascular and Metabolism portfolio and support relevant mature assets in the late phase portfolio • Leading a dedicated matrixed group of Subject Matter Experts and project team representatives as well as key program stakeholders, to together develop biomarkers strategies for disease and/or assets across the Research-Development-Commercial continuum • Representing Biomarker Development on Cardiovascular and Metabolism early and late Disease Area Decision Boards to identify, develop, and drive cardiovascular and metabolic disease and compound mechanistic biology, and precision medicine approaches for the portfolio • Leading strategic translational data working groups centered on integrating and analyzing large-scale patient muti-modal data sets (omics, imaging, digital, etc.) to identify new indications, endpoints, and responsive patient subpopulations • Representing BMD line functions in Therapeutic Area Line Function committees for clinical protocol development and operational milestone reviews • Leading biomarker strategies and drive plans at the clinical team level as a Biomarker Strategy Lead • Lead and/or contribute to BMD/TM/BR wide initiatives e.g. genetics, inflammation, imaging depending on background and expertise • Stay up to date on clinical, disease, biology and scientific literature and competitor data for their respective disease areas • Implementing strategies in close collaboration with the BMD global organization which includes over 150 associates with expertise in all aspects of biomarker science i.e. genetics, genomics, molecular and cellular, digital devices, imaging and data sciences • Design and present the RDC biomarker strategy for transitioning and mature assets for late phase within their key pillar and ensuring study level alignment across the portfolio segment of focus Essential Requirements: • MD, MD/PhD, or PhD degree required, plus additional PhD/postdoc or equivalent level research • Deep understanding of cardiovascular and metabolic disease epidemiology with particular emphasis on Atherosclerotic Cardiovascular Disease (ASCVD) that can be applied to questions of diagnosis, biomarker development and treatment monitoring strongly preferred • Scientific excellence supported by recognized high quality publications; clinical and/or biological expertise in cardiovascular and metabolic diseases (Board certified or similar level preferred) with impact in ASCVD literature • 5 plus years of independent leadership experience and external leadership/partnershi